IP Library Granted Patent US 7,846,722
Granted Patent B2
US 7,846,722 · App. 11/754,046 · Granted Dec 7, 2010

Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity

Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,846,722
App. No.
11/754,046
Granted
Dec 7, 2010
Kind
B2
Abstract

Clostridial toxin substrates comprising a lanthanide donor complex, an acceptor, and a Clostridial toxin recognition sequence including a cleavage site; methods for determining the activity of a Clostridial toxin from a test sample using such Clostridial toxin substrates; cell compositions comprising such Clostridial toxin substrates and a Clostridial toxin receptor; and methods for determining the activity of a Clostridial toxin from a test sample using such cell compositions.

Claims (26)

1. A cell composition comprising:

a. a Clostridial toxin substrate comprising

i. a lanthanide donor complex comprising a lanthanide binding site and a lanthanide ion;

ii. an acceptor;

iii. a Clostridial toxin recognition sequence including a P 1 -P 1 ′ cleavage site that intervenes between the lanthanide donor complex and the acceptor; and

iv. a membrane targeting domain;

wherein the acceptor has an absorbance spectrum overlapping the emission spectrum of the lanthanide donor complex; and

wherein, under the appropriate conditions, resonance energy transfer is exhibited between the lanthanide donor complex and the acceptor; and

b. a Clostridial toxin receptor capable of initiating the intoxication process by selectively binding a Clostridial toxin.

2. The composition according to 1 , wherein the Clostridial toxin receptor comprises an endogenous Clostridial toxin receptor.

3. The composition according to 1 , wherein the Clostridial toxin receptor comprises an exogenous Clostridial toxin receptor.

4. The composition according to 1 , wherein the cell is a neuronal cell.

5. The composition according to 1 , wherein the cell is a non-neuronal cell.

6. The substrate according to claim 1 , wherein the lanthanide binding site has a Kd for a lanthanide ion of less than 1 μM.

7. The composition according to claim 1 , wherein the lanthanide binding site comprises a chelate, a cryptate, or an EF-hand motif.

8. The composition according to claim 1 , wherein the acceptor is an acceptor fluorophore.

9. The composition according to claim 8 , wherein the acceptor fluorophore comprises a fluorescent protein, a fluorophore binding protein, or a fluorescent dye.

10. The composition according to claim 1 , wherein the acceptor is a non fluorescent acceptor.

11. The composition according to claim 1 , wherein the lanthanide donor complex further comprises an antenna.

12. The composition according to claim 11 , wherein the antenna is distinct from the lanthanide-binding site.

13. The composition according to claim 11 , wherein the antenna is incorporated with lanthanide biding site.

14. The composition according to claim 1 , wherein the substrate is a peptide having a length of at most 20 residues, at most 50 residues, at most 100 residues, or at most 150 residues.

15. The composition according to claim 1 , wherein the substrate is a peptide having a length of at least 100 residues, at least 300 residues, at least 500 residues, or at least 700 residues.

16. The composition according to claim 1 , wherein the Clostridial toxin recognition sequence is a peptide having a length of at most 20 residues, at most 30 residues, at most 40 residues or at most 50 residues.

17. The composition according to claim 1 , wherein the Clostridial toxin recognition sequence is a peptide having a length of at least 20 residues, at least 50 residues, at least 100 residues, or at least 200 residues.

18. The composition according to claim 1 , wherein the substrate can be cleaved with an activity of at least 1 nanomole/minute/milligram toxin, at least 20 nanomoles/minute/milligram toxin or at least 100 nanomoles/minute/milligram toxin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2007
From: WILLIAMS, DUDLEY J.; GILMORE, MARCELLA; VERHAGEN, MARC; FERNANDEZ-SALAS, ESTER; STEWARD, LANCE E.; AOKI, KEI ROGER
To: ALLERGAN, INC.
Reel/Frame 019381/0292 →
Continuity (4)
Continuation 1175259600 · May 23, 2007
Continuation In Part 0994209800 · Aug 28, 2001
Continuation In Part 1094707100 · Sep 21, 2004
Related Publication 20080220456A1 · Sep 11, 2008